Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23975881 | 0.92 | LMNA (0.45) | NOTUMSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL25312800 | 0.86 | NCOA3 (0.48) | SMN1; SMN2LMNAL3MBTL1POLBKMT2A | |
| SCHEMBL23975816 | 0.85 | L3MBTL1 (0.49) | SMN1; SMN2LMNAL3MBTL1KMT2ARAB9A | |
| SCHEMBL23991552 | 0.82 | KDM4E (0.46) | SMN1; SMN2LMNAALDH1A1KDM4EMEN1 | |
| SCHEMBL23975886 | 0.82 | KDM4E (0.48) | SMN1; SMN2LMNAALDH1A1KDM4EMEN1 | |
| SCHEMBL23976260 | 0.81 | KDM4E (0.46) | SMN1; SMN2LMNAALDH1A1KDM4EPOLB | |
| SCHEMBL23975855 | 0.79 | ALDH1A1 (0.44) | SMN1; SMN2LMNAALDH1A1L3MBTL1KDM4E | |
| SCHEMBL23976261 | 0.77 | METAP2 (0.44) | SMN1; SMN2LMNAALDH1A1L3MBTL1KDM4E | |
| SCHEMBL23991806 | 0.76 | LMNA (0.41) | NOTUMSMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL30411349 | 0.76 | LMNA (0.41) | NOTUMSMN1; SMN2LMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | Global Blood Therapeutics, Inc (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4142732-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143197-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222359-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222359-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | NOTUM 4249/4885SMN1; SMN2 1602/4885LMNA 1425/4885 |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | NOTUM 4469/4885SMN1; SMN2 2084/4885LMNA 2258/4885 |
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | HAMP, TFRC, SLC40A1 | NOTUM 4850/4885SMN1; SMN2 1963/4885LMNA 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.